Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

The discovery of regulated cell death processes has enabled advances in cancer treatment.
In the past decade, ferroptosis, an iron-dependent form of regulated cell death driven by …

Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …

Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death.
Despite tremendous progress in diagnosis and therapeutic strategies and significant …

Endocytosis is a complex process whereby cell surface proteins, lipids and fluid from the
extracellular environment are packaged, sorted and internalized into cells. Endocytosis is …

The RAS oncogene is both the most frequently mutated oncogene in human cancer and the
first confirmed human oncogene to be discovered in 1982. After decades of research, in …

Modern medicine has been waging a war on cancer for nearly a century with no tangible
end in sight. Cancer treatments have significantly progressed, but the need to increase …

Abstract The RAF-MEK-ERK signaling cascade is a well-characterized MAPK pathway
involved in cell proliferation and survival. The three-layered MAPK signaling cascade is …

KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

Purpose: Although KRAS represents the most commonly mutated oncogene, it has long
been considered an “undruggable” target. Novel covalent inhibitors selective for the …